{
    "hands_on_practices": [
        {
            "introduction": "A crucial first step in designing a meaningful PDX study is determining the appropriate drug dosage for the mice. Simply scaling a human dose by body weight is incorrect because metabolic rates and drug clearance do not scale linearly. This exercise guides you through the principles of allometric scaling, a cornerstone of preclinical pharmacology, to derive the correct mouse-equivalent dose that achieves comparable systemic exposure ($AUC$) to humans, ensuring your experimental results are translationally relevant .",
            "id": "5039628",
            "problem": "You are designing a dosing regimen for an efficacy study using patient-derived xenograft (PDX) models, where human tumor fragments are implanted into immunodeficient mice to preserve clinical tumor heterogeneity and drug response. To translate a clinically used human dose to a mouse-equivalent regimen that targets comparable systemic exposure, you adopt the following foundational pharmacokinetic assumptions: linear pharmacokinetics, identical route of administration with complete bioavailability across species, and an allometric relationship for systemic clearance such that $CL = k\\,W^{\\beta}$, where $CL$ is systemic clearance, $W$ is body weight, $k$ is a species-independent proportionality constant, and $\\beta$ is the allometric exponent. The pharmacologically relevant exposure metric is the area under the concentration-time curve (AUC), with $AUC \\propto \\dfrac{\\text{Dose}}{CL}$. The administered dose is expressed on a per kilogram basis, so that the absolute dose is $\\text{Dose} = d\\,W$, where $d$ has units $\\mathrm{mg/kg}$.\n\nStarting only from these fundamentals, derive the interspecies mg/kg scaling relation of the form $d_{\\mathrm{mouse}} = d_{\\mathrm{human}}\\left(\\dfrac{W_{\\mathrm{mouse}}}{W_{\\mathrm{human}}}\\right)^{\\theta}$, expressing the exponent $\\theta$ in terms of the clearance exponent $\\beta$. Then compute the mouse mg/kg dose that yields matched exposure to a human regimen with $d_{\\mathrm{human}} = 2.5$ $\\mathrm{mg/kg}$, taking $W_{\\mathrm{human}} = 70$ $\\mathrm{kg}$, $W_{\\mathrm{mouse}} = 0.020$ $\\mathrm{kg}$, and $\\beta = 0.75$.\n\nRound your final numerical answer to four significant figures and express it in $\\mathrm{mg/kg}$. Provide only the numerical value in your final boxed answer; do not include units inside the box.",
            "solution": "The central objective is to determine a dosing regimen for a mouse that achieves the same systemic drug exposure, measured by the area under the concentration-time curve ($AUC$), as a known regimen in a human. The problem states that for equivalent exposure, we must have:\n$$\nAUC_{\\mathrm{mouse}} = AUC_{\\mathrm{human}}\n$$\nThe problem provides a proportionality for $AUC$:\n$$\nAUC \\propto \\frac{\\text{Dose}}{CL}\n$$\nwhere `Dose` is the absolute amount of drug administered and $CL$ is the systemic clearance. Since the proportionality constant is independent of species, the condition for matched exposure becomes an equality:\n$$\n\\frac{\\text{Dose}_{\\mathrm{mouse}}}{CL_{\\mathrm{mouse}}} = \\frac{\\text{Dose}_{\\mathrm{human}}}{CL_{\\mathrm{human}}}\n$$\nWe are given two further constitutive relations. First, the absolute dose is defined in terms of a dose per unit body weight, $d$, and the body weight, $W$:\n$$\n\\text{Dose} = d \\cdot W\n$$\nSecond, the systemic clearance, $CL$, is related to body weight, $W$, through an allometric scaling law:\n$$\nCL = k\\,W^{\\beta}\n$$\nHere, $k$ is a species-independent proportionality constant and $\\beta$ is the allometric exponent.\n\nWe can now substitute these two relations into the exposure equality equation. For the mouse and human, respectively, we have:\n$$\n\\frac{d_{\\mathrm{mouse}} \\cdot W_{\\mathrm{mouse}}}{k\\,(W_{\\mathrm{mouse}})^{\\beta}} = \\frac{d_{\\mathrm{human}} \\cdot W_{\\mathrm{human}}}{k\\,(W_{\\mathrm{human}})^{\\beta}}\n$$\nThe species-independent constant $k$ cancels from both sides of the equation:\n$$\n\\frac{d_{\\mathrm{mouse}} \\cdot W_{\\mathrm{mouse}}}{(W_{\\mathrm{mouse}})^{\\beta}} = \\frac{d_{\\mathrm{human}} \\cdot W_{\\mathrm{human}}}{(W_{\\mathrm{human}})^{\\beta}}\n$$\nUsing the property of exponents $\\frac{x^a}{x^b} = x^{a-b}$, we simplify both sides:\n$$\nd_{\\mathrm{mouse}} \\cdot (W_{\\mathrm{mouse}})^{1-\\beta} = d_{\\mathrm{human}} \\cdot (W_{\\mathrm{human}})^{1-\\beta}\n$$\nOur goal is to find an expression for $d_{\\mathrm{mouse}}$ in terms of $d_{\\mathrm{human}}$. We rearrange the equation to solve for $d_{\\mathrm{mouse}}$:\n$$\nd_{\\mathrm{mouse}} = d_{\\mathrm{human}} \\cdot \\frac{(W_{\\mathrm{human}})^{1-\\beta}}{(W_{\\mathrm{mouse}})^{1-\\beta}}\n$$\nThis can be written more compactly as:\n$$\nd_{\\mathrm{mouse}} = d_{\\mathrm{human}} \\left(\\frac{W_{\\mathrm{human}}}{W_{\\mathrm{mouse}}}\\right)^{1-\\beta}\n$$\nThe problem requests the scaling relation in the form $d_{\\mathrm{mouse}} = d_{\\mathrm{human}}\\left(\\frac{W_{\\mathrm{mouse}}}{W_{\\mathrm{human}}}\\right)^{\\theta}$. To match this form, we must invert the fraction inside the parentheses, which is equivalent to negating the exponent:\n$$\nd_{\\mathrm{mouse}} = d_{\\mathrm{human}} \\left( \\left(\\frac{W_{\\mathrm{mouse}}}{W_{\\mathrm{human}}}\\right)^{-1} \\right)^{1-\\beta} = d_{\\mathrm{human}} \\left(\\frac{W_{\\mathrm{mouse}}}{W_{\\mathrm{human}}}\\right)^{-(1-\\beta)}\n$$\nSimplifying the exponent, we get:\n$$\nd_{\\mathrm{mouse}} = d_{\\mathrm{human}} \\left(\\frac{W_{\\mathrm{mouse}}}{W_{\\mathrm{human}}}\\right)^{\\beta - 1}\n$$\nBy comparing this derived expression with the requested form, we can identify the exponent $\\theta$:\n$$\n\\theta = \\beta - 1\n$$\nThis completes the first part of the problem.\n\nFor the second part, we must compute the numerical value for the mouse dose, $d_{\\mathrm{mouse}}$, using the supplied data:\n$d_{\\mathrm{human}} = 2.5$ $\\mathrm{mg/kg}$\n$W_{\\mathrm{human}} = 70$ $\\mathrm{kg}$\n$W_{\\mathrm{mouse}} = 0.020$ $\\mathrm{kg}$\n$\\beta = 0.75$\n\nFirst, we calculate the exponent $\\theta$:\n$$\n\\theta = \\beta - 1 = 0.75 - 1 = -0.25\n$$\nNow, we substitute the values into the derived scaling relation:\n$$\nd_{\\mathrm{mouse}} = d_{\\mathrm{human}} \\left(\\frac{W_{\\mathrm{mouse}}}{W_{\\mathrm{human}}}\\right)^{\\theta} = 2.5 \\left(\\frac{0.020}{70}\\right)^{-0.25}\n$$\nLet's evaluate the expression:\n$$\nd_{\\mathrm{mouse}} = 2.5 \\left(\\frac{2 \\times 10^{-2}}{7 \\times 10^1}\\right)^{-0.25} = 2.5 \\left(\\frac{1}{3500}\\right)^{-0.25}\n$$\nUsing the property $x^{-a} = \\frac{1}{x^a}$, we have $(1/3500)^{-0.25} = (3500)^{0.25}$.\n$$\nd_{\\mathrm{mouse}} = 2.5 \\times (3500)^{0.25}\n$$\nCalculating the numerical value:\n$$\n(3500)^{0.25} = (3500)^{1/4} \\approx 7.69160352\n$$\n$$\nd_{\\mathrm{mouse}} \\approx 2.5 \\times 7.69160352 \\approx 19.2290088\n$$\nThe problem requires the final answer to be rounded to four significant figures. Therefore, the mouse-equivalent dose is $19.23$ $\\mathrm{mg/kg}$.",
            "answer": "$$ \\boxed{19.23} $$"
        },
        {
            "introduction": "After establishing the correct dose, the next critical design question is: how many mice are needed per group to reliably detect a treatment effect? Answering this requires a statistical power analysis, which balances the desired sensitivity against ethical and resource constraints. This problem walks you through a realistic sample size calculation for a PDX study, incorporating a sophisticated log-linear model of tumor growth and accounting for both within-mouse measurement variability and between-mouse biological heterogeneity .",
            "id": "5039622",
            "problem": "In a study using Patient-Derived Xenograft (PDX) models, tumor volumes are measured longitudinally on each mouse at times $t \\in \\{0, 3, 6, 9, 12\\}$ days. It is well-established that, over short experimental windows, solid tumor growth in immunodeficient mice can be approximated by exponential growth, so that the tumor volume $V(t)$ for mouse $i$ follows $V_{i}(t) = V_{0,i} \\exp(r_{i} t)$, where $r_{i}$ is the individual tumor growth rate. Under the log-transform $y_{i}(t) = \\ln V_{i}(t)$, this induces the linear model $y_{i}(t) = \\alpha_{i} + r_{i} t + \\varepsilon_{i}(t)$, where $\\varepsilon_{i}(t)$ are independent, mean-zero, homoscedastic errors across times and mice.\n\nPilot data in a control cohort (untreated) fitted to the log-linear model yield the following variance component estimates: residual variance on the log scale $\\sigma_{\\varepsilon}^{2} = 0.01$ and between-mouse variance in true growth rates $\\sigma_{r}^{2} = 4.0 \\times 10^{-4}$ (with $r_{i}$ measured in $\\text{day}^{-1}$). The pilot also estimates the mean control growth rate as $r_{C} = 0.08$ $\\text{day}^{-1}$. You are planning a two-arm study with equal allocation (control versus treatment) that will use the same measurement schedule $\\{0, 3, 6, 9, 12\\}$ days and the same log-linear analysis. For each mouse, you will estimate its slope $\\hat{r}_{i}$ by ordinary least squares (OLS) from the log-volume versus time regression, and then compare the group mean slopes between treatment and control using a normal-approximation two-sided test under homoscedasticity.\n\nAssume the treatment reduces the mean growth rate by $30\\%$ relative to control, while leaving the variance components unchanged, and that mice are independent both within and between arms. Use a two-sided type I error rate $\\alpha = 0.05$ and desired power $1 - \\beta = 0.8$. Starting from the log-linear model and the properties of ordinary least squares and the normal approximation, derive the required per-arm sample size to detect the planned reduction in mean growth rate. Treat the $z$-quantiles as those of the standard normal distribution, and express any intermediate analytic steps symbolically before substituting numerical values. Report the minimal integer sample size per arm required to achieve the design objectives. The final answer should be a single integer (no units).",
            "solution": "### Step 1: Extract Givens\n-   **Model:** The tumor volume $V_{i}(t)$ for mouse $i$ is given by $V_{i}(t) = V_{0,i} \\exp(r_{i} t)$.\n-   **Log-Linear Model:** The log-transformed volume $y_{i}(t) = \\ln V_{i}(t)$ follows a linear model $y_{i}(t) = \\alpha_{i} + r_{i} t + \\varepsilon_{i}(t)$.\n-   **Error Structure:** The errors $\\varepsilon_{i}(t)$ are independent, with mean $E[\\varepsilon_{i}(t)]=0$ and constant variance $\\sigma_{\\varepsilon}^{2}$.\n-   **Measurement Times:** $t \\in \\{0, 3, 6, 9, 12\\}$ days.\n-   **Variance Components:**\n    -   Residual variance on log scale: $\\sigma_{\\varepsilon}^{2} = 0.01$.\n    -   Between-mouse variance in true growth rates: $\\sigma_{r}^{2} = 4.0 \\times 10^{-4}$ $\\text{day}^{-2}$.\n-   **Control Group Parameter:** Mean control growth rate is $r_{C} = 0.08$ $\\text{day}^{-1}$.\n-   **Study Design:** Two-arm study (control vs. treatment) with equal allocation, $n$ mice per arm.\n-   **Analysis Plan:**\n    1.  Estimate individual growth rates $\\hat{r}_{i}$ via Ordinary Least Squares (OLS) from log-volume vs. time regression.\n    2.  Compare group mean slopes ($\\bar{r}_{C}$ vs. $\\bar{r}_{T}$) using a normal-approximation two-sided test.\n-   **Treatment Effect:** The treatment reduces the mean growth rate by $30\\%$ relative to control. Variance components are assumed to be unchanged.\n-   **Statistical Parameters:**\n    -   Type I error rate: $\\alpha = 0.05$ (two-sided).\n    -   Desired power: $1 - \\beta = 0.8$.\n-   **Objective:** Derive the required per-arm sample size, $n$.\n\n### Derivation of the Solution\nThe central task is to determine the sample size $n$ per arm required to detect a specified difference in mean growth rates between a treatment and a control group with $80\\%$ power at a $5\\%$ significance level.\n\n**1. Variance of the Estimated Individual Growth Rate**\n\nFor each mouse $i$, the true log-linear model is $y_{i}(t) = \\alpha_{i} + r_{i} t + \\varepsilon_{i}(t)$. We have $k=5$ measurements at times $t_{j} \\in \\{0, 3, 6, 9, 12\\}$. The growth rate $r_{i}$ is estimated using an OLS regression of $y_{i}$ on $t$. The OLS estimator for the slope is given by:\n$$ \\hat{r}_{i} = \\frac{\\sum_{j=1}^{k} (t_{j} - \\bar{t})(y_{ij} - \\bar{y}_i)}{\\sum_{j=1}^{k} (t_{j} - \\bar{t})^2} $$\nSubstituting the model for $y_{ij}$, we find that the estimator can be expressed as:\n$$ \\hat{r}_{i} = r_{i} + \\frac{\\sum_{j=1}^{k} (t_{j} - \\bar{t})\\varepsilon_{ij}}{\\sum_{j=1}^{k} (t_{j} - \\bar{t})^2} $$\nThis shows that conditional on the true individual rate $r_i$, the estimator $\\hat{r}_i$ is unbiased, $E[\\hat{r}_{i}|r_{i}] = r_{i}$.\n\nThe variance of the estimator, conditional on $r_{i}$, is due to the measurement error $\\varepsilon_{ij}$:\n$$ \\text{Var}(\\hat{r}_{i} | r_{i}) = \\text{Var}\\left( \\frac{\\sum_{j=1}^{k} (t_{j} - \\bar{t})\\varepsilon_{ij}}{\\sum_{j=1}^{k} (t_{j} - \\bar{t})^2} \\right) = \\frac{\\sum_{j=1}^{k} (t_{j} - \\bar{t})^2 \\text{Var}(\\varepsilon_{ij})}{\\left(\\sum_{j=1}^{k} (t_{j} - \\bar{t})^2\\right)^2} = \\frac{\\sigma_{\\varepsilon}^2}{S_{tt}} $$\nwhere $S_{tt} = \\sum_{j=1}^{k} (t_{j} - \\bar{t})^2$. The time points are $\\{0, 3, 6, 9, 12\\}$.\nThe mean time is $\\bar{t} = \\frac{0+3+6+9+12}{5} = \\frac{30}{5} = 6$ days.\nThe sum of squared deviations is:\n$$ S_{tt} = (0-6)^2 + (3-6)^2 + (6-6)^2 + (9-6)^2 + (12-6)^2 $$\n$$ S_{tt} = (-6)^2 + (-3)^2 + 0^2 + 3^2 + 6^2 = 36 + 9 + 0 + 9 + 36 = 90 \\; \\text{days}^2 $$\nSo, the conditional variance is $\\text{Var}(\\hat{r}_{i} | r_{i}) = \\frac{\\sigma_{\\varepsilon}^2}{90}$.\n\nThe estimated slope $\\hat{r}_i$ for a randomly selected mouse is a random variable subject to two sources of variance: the within-mouse measurement error and the between-mouse biological variation in true growth rates, $r_i \\sim \\mathcal{N}(\\mu_r, \\sigma_r^2)$. The total variance of a single observation $\\hat{r}_i$ is found using the law of total variance:\n$$ \\sigma_{\\hat{r}}^2 = \\text{Var}(\\hat{r}_{i}) = E[\\text{Var}(\\hat{r}_{i}|r_{i})] + \\text{Var}(E[\\hat{r}_{i}|r_{i}]) $$\n$$ \\sigma_{\\hat{r}}^2 = E\\left[\\frac{\\sigma_{\\varepsilon}^2}{S_{tt}}\\right] + \\text{Var}(r_{i}) $$\n$$ \\sigma_{\\hat{r}}^2 = \\frac{\\sigma_{\\varepsilon}^2}{S_{tt}} + \\sigma_{r}^2 $$\nThis is the variance of a single estimated slope, which will be the basis for our sample size calculation.\n\n**2. Sample Size Calculation**\n\nThe hypothesis test compares the means of the estimated slopes from the control group ($\\bar{r}_C$) and the treatment group ($\\bar{r}_T$).\nNull hypothesis $H_0: \\mu_C = \\mu_T$.\nAlternative hypothesis $H_1: \\mu_C \\neq \\mu_T$.\nThe sample size $n$ per arm for a two-sample z-test is given by the formula:\n$$ n = \\frac{2 \\sigma_{\\hat{r}}^2 (z_{\\alpha/2} + z_{\\beta})^2}{(\\mu_C - \\mu_T)^2} $$\nwhere $\\mu_C=r_C$ and $\\mu_T=r_T$ are the population mean growth rates, $\\Delta = \\mu_C - \\mu_T$ is the effect size, $\\sigma_{\\hat{r}}^2$ is the variance of a single observation $\\hat{r}_i$ (assumed equal in both groups), $z_{\\alpha/2}$ is the standard normal quantile for the significance level $\\alpha$, and $z_{\\beta}$ is the standard normal quantile for the desired power $1-\\beta$.\n\n**3. Substituting Numerical Values**\n\nWe are given:\n-   Significance level: $\\alpha = 0.05$ (two-sided) $\\implies z_{\\alpha/2} = z_{0.025} = 1.96$.\n-   Power: $1-\\beta = 0.8 \\implies \\beta = 0.2 \\implies z_{\\beta} = z_{0.2} \\approx 0.8416$.\n-   Variance components: $\\sigma_{\\varepsilon}^2=0.01$ and $\\sigma_{r}^2=4.0 \\times 10^{-4} = 0.0004$.\n-   Time-point summary: $S_{tt} = 90$.\n\nFirst, calculate the total variance $\\sigma_{\\hat{r}}^2$:\n$$ \\sigma_{\\hat{r}}^2 = \\frac{0.01}{90} + 0.0004 = \\frac{1}{9000} + \\frac{4}{10000} = \\frac{10}{90000} + \\frac{36}{90000} = \\frac{46}{90000} = \\frac{23}{45000} \\; \\text{day}^{-2} $$\nAs a decimal, $\\sigma_{\\hat{r}}^2 \\approx 0.0005111... \\; \\text{day}^{-2}$.\n\nNext, calculate the effect size $\\Delta = \\mu_C - \\mu_T$.\n-   Mean control rate: $\\mu_C = r_C = 0.08 \\; \\text{day}^{-1}$.\n-   The treatment reduces this rate by $30\\%$.\n-   Mean treatment rate: $\\mu_T = r_C \\times (1 - 0.30) = 0.08 \\times 0.7 = 0.056 \\; \\text{day}^{-1}$.\n-   The difference is $\\Delta = 0.08 - 0.056 = 0.024 \\; \\text{day}^{-1}$.\n\nNow, substitute all values into the sample size formula:\n$$ n = \\frac{2 \\left(\\frac{23}{45000}\\right) (1.96 + 0.8416)^2}{(0.024)^2} $$\n$$ n = \\frac{2 \\left(\\frac{23}{45000}\\right) (2.8016)^2}{0.000576} $$\n$$ n \\approx \\frac{2 \\times (0.0005111) \\times (7.84896)}{0.000576} $$\n$$ n \\approx \\frac{0.0010222 \\times 7.84896}{0.000576} $$\n$$ n \\approx \\frac{0.008021}{0.000576} \\approx 13.925 $$\nTo be more precise with fractions:\n$$ n = \\frac{2 \\times \\frac{23}{45000} \\times (2.8016)^2}{(0.024)^2} = \\frac{\\frac{46}{45000} \\times 7.84896256}{0.000576} = \\frac{0.00802157...}{0.000576} \\approx 13.926...$$\nThe sample size $n$ must be an integer. To achieve a power of at least $0.8$, we must round the calculated value up to the next whole number.\n$$ n = \\lceil 13.926... \\rceil = 14 $$\nTherefore, the minimal required sample size is $14$ mice per arm.",
            "answer": "$$\\boxed{14}$$"
        },
        {
            "introduction": "Once your experiment is complete and tumor volumes have been collected, the final step is to quantify the treatment's effectiveness. A standard metric for this is Tumor Growth Inhibition ($TGI$), but its calculation requires careful consideration of the experimental data to avoid misleading conclusions. This exercise demonstrates how to correctly derive and compute $TGI$ by normalizing for differences in baseline tumor sizes, a common challenge in PDX studies, ensuring a robust and accurate assessment of drug efficacy .",
            "id": "5039689",
            "problem": "In a translational medicine study using Patient-Derived Xenograft (PDX) models, a single patientâ€™s tumor was propagated into two cohorts of immunodeficient mice: a vehicle control cohort and a drug-treated cohort. Group-average tumor volumes were measured at baseline ($t=0$) and at a fixed endpoint time $t^{\\ast} = 21$ days. Let $V_{\\mathrm{control}}(t)$ and $V_{\\mathrm{treated}}(t)$ denote the cohort-average tumor volumes at time $t$ for control and treated groups, respectively. The recorded values are: $V_{\\mathrm{control}}(0)=105\\,\\mathrm{mm}^{3}$, $V_{\\mathrm{control}}(21)=315\\,\\mathrm{mm}^{3}$, $V_{\\mathrm{treated}}(0)=145\\,\\mathrm{mm}^{3}$, and $V_{\\mathrm{treated}}(21)=210\\,\\mathrm{mm}^{3}$. Using first principles appropriate to PDX efficacy assessment, derive the expression for Tumor Growth Inhibition (TGI) at $t^{\\ast}$ as a dimensionless measure that compares the drug-induced change in tumor volume to the change that would be observed in the absence of treatment, and then compute the TGI at $t^{\\ast}=21$ days from the provided data. Explain, based on your derivation, the correct interpretation of TGI when baseline volumes differ between cohorts, and why endpoint volumes alone are not an appropriate basis for comparison in such cases. Express the final TGI value as a decimal, rounded to four significant figures, with no percent sign.",
            "solution": "The core task is to derive a dimensionless measure for Tumor Growth Inhibition (TGI) that compares the effect of a drug treatment to a control condition. The problem specifies that this measure should compare the \"drug-induced change in tumor volume to the change that would be observed in the absence of treatment.\" This directive constitutes the first principle for our derivation.\n\nLet $V_{\\mathrm{control}}(t)$ and $V_{\\mathrm{treated}}(t)$ represent the average tumor volumes at time $t$ for the control and treated cohorts, respectively. The experiment is observed from a baseline time $t=0$ to an endpoint time $t^{\\ast}$.\n\nFirst, we define the change in tumor volume, or tumor growth, over the experimental period $[0, t^{\\ast}]$ for each cohort.\n\nThe change in volume for the control group is:\n$$ \\Delta V_{\\mathrm{control}} = V_{\\mathrm{control}}(t^{\\ast}) - V_{\\mathrm{control}}(0) $$\nThis quantity, $\\Delta V_{\\mathrm{control}}$, represents the natural growth of the tumor over the time period $t^{\\ast}$ in the absence of the therapeutic agent.\n\nThe change in volume for the treated group is:\n$$ \\Delta V_{\\mathrm{treated}} = V_{\\mathrm{treated}}(t^{\\ast}) - V_{\\mathrm{treated}}(0) $$\nThis quantity, $\\Delta V_{\\mathrm{treated}}$, represents the net growth of the tumor under the influence of the drug.\n\nThe \"inhibition\" of growth due to the drug is the difference between the growth that would have occurred (control growth) and the growth that was actually observed (treated growth). We can express this absolute growth inhibition as:\n$$ \\text{Absolute Growth Inhibition} = \\Delta V_{\\mathrm{control}} - \\Delta V_{\\mathrm{treated}} $$\nTo create a dimensionless, relative measure as required, we normalize this absolute inhibition by the growth that would have occurred without treatment, which is $\\Delta V_{\\mathrm{control}}$. This yields the standard formula for TGI:\n$$ \\text{TGI} = \\frac{\\Delta V_{\\mathrm{control}} - \\Delta V_{\\mathrm{treated}}}{\\Delta V_{\\mathrm{control}}} $$\nThis expression can be simplified to:\n$$ \\text{TGI} = 1 - \\frac{\\Delta V_{\\mathrm{treated}}}{\\Delta V_{\\mathrm{control}}} $$\nSubstituting the definitions for $\\Delta V_{\\mathrm{control}}$ and $\\Delta V_{\\mathrm{treated}}$, we arrive at the full expression for TGI based on the measured volumes:\n$$ \\text{TGI} = 1 - \\frac{V_{\\mathrm{treated}}(t^{\\ast}) - V_{\\mathrm{treated}}(0)}{V_{\\mathrm{control}}(t^{\\ast}) - V_{\\mathrm{control}}(0)} $$\nThis derived expression is the required dimensionless measure.\n\nThe problem asks for an explanation of the correct interpretation of TGI when baseline volumes differ. The derived formula shows that TGI is not based on the final tumor volumes $V(t^{\\ast})$ alone, but on the *change* in volumes, $\\Delta V$. This is critical. In a typical PDX experiment, even with careful staging, there will be variation in the initial tumor volumes ($V(0)$) between cohorts. If one were to compare only the endpoint volumes, for instance by calculating the ratio $V_{\\mathrm{treated}}(t^{\\ast}) / V_{\\mathrm{control}}(t^{\\ast})$, any pre-existing difference in baseline volumes would confound the interpretation of the drug's effect. For example, if the treated group started with significantly larger tumors, its final volume might still be larger than the control group's final volume, even if the drug were highly effective at slowing growth. This could lead to the erroneous conclusion that the drug is ineffective or even promotes growth. The TGI metric, by focusing on the net change $\\Delta V$, mathematically normalizes for differences in starting volumes. It correctly evaluates the treatment's effect on the *rate of growth* relative to the natural growth rate, which is the biologically and pharmacologically relevant question. Therefore, using endpoint volumes alone is not an appropriate basis for comparison when baseline volumes are unequal because it conflates the treatment effect with initial experimental conditions.\n\nNow, we compute the TGI at $t^{\\ast} = 21$ days using the provided data:\n$V_{\\mathrm{control}}(0) = 105\\,\\mathrm{mm}^{3}$\n$V_{\\mathrm{control}}(21) = 315\\,\\mathrm{mm}^{3}$\n$V_{\\mathrm{treated}}(0) = 145\\,\\mathrm{mm}^{3}$\n$V_{\\mathrm{treated}}(21) = 210\\,\\mathrm{mm}^{3}$\n\nFirst, we calculate the change in volume for each cohort.\nFor the control cohort:\n$$ \\Delta V_{\\mathrm{control}} = 315\\,\\mathrm{mm}^{3} - 105\\,\\mathrm{mm}^{3} = 210\\,\\mathrm{mm}^{3} $$\nFor the treated cohort:\n$$ \\Delta V_{\\mathrm{treated}} = 210\\,\\mathrm{mm}^{3} - 145\\,\\mathrm{mm}^{3} = 65\\,\\mathrm{mm}^{3} $$\nNow, we substitute these values into the TGI formula:\n$$ \\text{TGI} = 1 - \\frac{\\Delta V_{\\mathrm{treated}}}{\\Delta V_{\\mathrm{control}}} = 1 - \\frac{65}{210} $$\nThe ratio is:\n$$ \\frac{65}{210} \\approx 0.3095238... $$\nTherefore, the TGI is:\n$$ \\text{TGI} = 1 - 0.3095238... = 0.6904761... $$\nThe problem requires the final answer to be rounded to four significant figures.\n$$ \\text{TGI} \\approx 0.6905 $$\nThis value signifies that the treatment inhibited tumor growth by approximately $69.05\\%$ compared to the growth observed in the control group over the $21$-day period.",
            "answer": "$$\\boxed{0.6905}$$"
        }
    ]
}